Ascendis Pharma A/S
ASND
Kedudukan dalam Saham
#1503
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Harga Saham
$234.90
Modal Pasaran
$14.65B
Perubahan (1 hari)
2.15%
Perubahan (1 tahun)
14.47%
Negara
DK
Perdagangan Ascendis Pharma A/S (ASND)
Kategori
Healthcare
Sejarah pecahan saham untuk Ascendis Pharma A/S (ASND)
Saham Ascendis Pharma A/S (simbol: ASND) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham ASND yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham ASND.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham ASND yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham ASND.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|